Frontiers An overview of agents and treatments for PDGFRA

lt;p>Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–15% of gastrointestinal stromal tumors (GISTs). These tumors with P

Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment

Schematic representation of KIT and PDGFRA mutations found in GISTs.

Full article: Pharmacogenetics in the treatment of gastrointestinal stromal tumors – an updated review

Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward - M. Julia Lostes-Bardaji, David García-Illescas, Claudia Valverde, César Serrano, 2021

Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates - Abstract - Europe PMC

IJMS, Free Full-Text

Small molecule inhibitors targeting the cancers - Liu - 2022 - MedComm - Wiley Online Library

Next Generation of PDGFR Inhibitors Makes Headway in GIST

Temporal control of PDGFRα regulates the fibroblast-to-myofibroblast transition in wound healing - ScienceDirect

PDGFR signal transduction and links to the cytoskeleton. (A) The

Gastrointestinal Stromal Tumors: The GIST of Precision Medicine.

Various Protein Kinase Inhibitors as Anticancer Agents

Prenatal overexpression of platelet‐derived growth factor receptor A results in central nervous system hypomyelination - Cardona - 2021 - Brain and Behavior - Wiley Online Library

Frontiers An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors

Gastrointestinal stromal tumor: a review of current and emerging therapies